Switch theme
Sign up to access all valuation multiples
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
2013
65
LTM Revenue n/a
LTM EBITDA -$208M
$630M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Spyre Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of -$208M.
In the most recent fiscal year, Spyre Therapeutics achieved revenue of n/a and an EBITDA of -$209M.
Spyre Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Spyre Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.9M | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$128M | -$209M | XXX | XXX | XXX |
| EBITDA Margin | -14427% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$83.8M | -$339M | XXX | XXX | XXX |
| Net Margin | -9460% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Spyre Therapeutics's stock price is $13.
Spyre Therapeutics has current market cap of $785M, and EV of $630M.
See Spyre Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $630M | $785M | XXX | XXX | XXX | XXX | $-3.26 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Spyre Therapeutics has market cap of $785M and EV of $630M.
Spyre Therapeutics's trades at n/a LTM EV/Revenue multiple, and -3.0x LTM EBITDA.
Analysts estimate Spyre Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Spyre Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $630M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -3.0x | XXX | XXX | XXX |
| P/E | -3.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -4.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSpyre Therapeutics's NTM/LTM revenue growth is n/a
Spyre Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $3.2M for the same period.
Over next 12 months, Spyre Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Spyre Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Spyre Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -100% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 63% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $3.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Spyre Therapeutics acquired XXX companies to date.
Last acquisition by Spyre Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Spyre Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Spyre Therapeutics founded? | Spyre Therapeutics was founded in 2013. |
| Where is Spyre Therapeutics headquartered? | Spyre Therapeutics is headquartered in United States of America. |
| How many employees does Spyre Therapeutics have? | As of today, Spyre Therapeutics has 65 employees. |
| Who is the CEO of Spyre Therapeutics? | Spyre Therapeutics's CEO is Dr. Cameron Turtle, D.Phil.. |
| Is Spyre Therapeutics publicy listed? | Yes, Spyre Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Spyre Therapeutics? | Spyre Therapeutics trades under SYRE ticker. |
| When did Spyre Therapeutics go public? | Spyre Therapeutics went public in 2016. |
| Who are competitors of Spyre Therapeutics? | Similar companies to Spyre Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Spyre Therapeutics? | Spyre Therapeutics's current market cap is $785M |
| What is the current EBITDA of Spyre Therapeutics? | Spyre Therapeutics's last 12-month EBITDA is -$208M. |
| What is the current EV/EBITDA multiple of Spyre Therapeutics? | Current EBITDA multiple of Spyre Therapeutics is -3.0x. |
| Is Spyre Therapeutics profitable? | Yes, Spyre Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
